I ask Agenus to consider Armenia as the first country to register the BOT/BAL combination: Gevorg Tamamyan
“~20% ORR and 90% alive at 6 months in comparison to ZERO!
How many patients will be lost until the completion of phase 3?
I ask Agenus to consider Armenia as the first country to register the BOT/BAL combination! Our team is ready to provide this life-saving therapy to patients from all over the world! Patients cannot wait!” wrote Dr. Gevorg Tamamyan, Editor-in-Chief of OncoDaily and Professor at Yerevan State Medical University, on his LinkedIn page.
He shared a previously published post by Dr. Steven O’Day, Chief Medical Officer of Agenus, about making the BOT/BAL combination available to patients.
Earlier, Agenus announced that “Preliminary Phase 2 data tracks with Phase 1 BOT/BAL clinical activity in MSS mCRC (ORR ~19.4% and 90% alive at 6 months)”, however, despite this, “the FDA advised against submission of these results in support of an Accelerated Approval based on their view that objective response rates may not translate to a survival benefit.”
They also announced that “in addition to progress in the U.S., Agenus is advancing its efforts to bring BOT/BAL to patients in Europe.”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023